

Accepted Manuscript

Microbiological Activity of Ceftolozane/Tazobactam, Ceftazidime, Meropenem, and Piperacillin/Tazobactam against *Pseudomonas aeruginosa* isolated from Children with Cystic Fibrosis

Joseph L. Kuti, Rebecca S. Pettit, Natalie Neu, Jeffrey J. Cies, Craig Lapin, Marianne S. Muhlebach, Kimberly J. Novak, Sean T. Nguyen, Lisa Saiman, David P. Nicolau

PII: S0732-8893(15)00134-0
DOI: doi: [10.1016/j.diagmicrobio.2015.04.012](https://doi.org/10.1016/j.diagmicrobio.2015.04.012)
Reference: DMB 13816

To appear in: *Diagnostic Microbiology and Infectious Disease*

Received date: 23 March 2015
Revised date: 24 April 2015
Accepted date: 26 April 2015

Please cite this article as: Kuti Joseph L., Pettit Rebecca S., Neu Natalie, Cies Jeffrey J., Lapin Craig, Muhlebach Marianne S., Novak Kimberly J., Nguyen Sean T., Saiman Lisa, Nicolau David P., Microbiological Activity of Ceftolozane/Tazobactam, Ceftazidime, Meropenem, and Piperacillin/Tazobactam against *Pseudomonas aeruginosa* isolated from Children with Cystic Fibrosis, *Diagnostic Microbiology and Infectious Disease* (2015), doi: [10.1016/j.diagmicrobio.2015.04.012](https://doi.org/10.1016/j.diagmicrobio.2015.04.012)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Version Date: April 21, 2015

DMID-15-223

Microbiological Activity of Ceftolozane/Tazobactam, Ceftazidime, Meropenem, and Piperacillin/Tazobactam against *Pseudomonas aeruginosa* isolated from Children with Cystic Fibrosis

Joseph L. Kuti^{a#}, Rebecca S. Pettit^b, Natalie Neu^c, Jeffrey J. Cies^d, Craig Lapin^e,
Marianne S. Muhlebach^f, Kimberly J. Novak^g, Sean T. Nguyen^{h1}, Lisa Saiman^c, David P.
Nicolau^a

^a Center for Anti-Infective Research & Development, Hartford Hospital, Hartford CT; ^b Riley Hospital for Children, Indianapolis IN; ^c Columbia University, New York NY; ^d St. Christopher's Hospital for Children, Philadelphia PA; ^e CT Children's Medical Center, Hartford CT; ^f University of North Carolina, Chapel Hill NC; ^g Nationwide Children's Hospital, Columbus OH; ^h Children's Medical Center, Dallas TX

¹ Present address: Actavis plc, Parsippany, NJ

Running Title: TOL/TAZ activity against CF P. aeruginosa

Corresponding Author: Joseph L. Kuti, PharmD, Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102 USA. Tel: 1-860-972-3612; Fax: 1-860-545-3992; Email: joseph.kuti@hhchealth.org

Download English Version:

<https://daneshyari.com/en/article/6115588>

Download Persian Version:

<https://daneshyari.com/article/6115588>

[Daneshyari.com](https://daneshyari.com)